Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf; Steven M Larson; Aseem Anand; Michael J Morris; Susan F Slovin; David R Shaffer; Glenn Heller; Brett Carver; Neal Rosen; Howard I Scher

doi:10.1002/cncr.29578

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf, Steven M Larson, Aseem Anand, Michael J Morris, Susan F Slovin, David R Shaffer, Glenn Heller, Brett Carver, Neal Rosen, Howard I Scher

Urologisk cancerforskning, Malmö

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

Originalspråk	engelska
Sidor (från-till)	3853-3861
Tidskrift	Cancer
Volym	121
Nummer	21
DOI	https://doi.org/10.1002/cncr.29578
Status	Published - 2015

Ämnesklassifikation (UKÄ)

Urologi och njurmedicin

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1002/cncr.29578

http://www.ncbi.nlm.nih.gov/pubmed/26178426?dopt=Abstract

Citera det här

@article{4c5f3dbc1bd0459e89d1c90787e1708d,

title = "Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.",

abstract = "The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).",

author = "Rathkopf, {Dana E} and Larson, {Steven M} and Aseem Anand and Morris, {Michael J} and Slovin, {Susan F} and Shaffer, {David R} and Glenn Heller and Brett Carver and Neal Rosen and Scher, {Howard I}",

year = "2015",

doi = "10.1002/cncr.29578",

language = "English",

volume = "121",

pages = "3853--3861",

journal = "Cancer",

issn = "1097-0142",

publisher = "John Wiley & Sons Inc.",

number = "21",

}

TY - JOUR

T1 - Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

AU - Rathkopf, Dana E

AU - Larson, Steven M

AU - Anand, Aseem

AU - Morris, Michael J

AU - Slovin, Susan F

AU - Shaffer, David R

AU - Heller, Glenn

AU - Carver, Brett

AU - Rosen, Neal

AU - Scher, Howard I

PY - 2015

Y1 - 2015

N2 - The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

AB - The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

U2 - 10.1002/cncr.29578

DO - 10.1002/cncr.29578

M3 - Article

C2 - 26178426

SN - 1097-0142

VL - 121

SP - 3853

EP - 3861

JO - Cancer

JF - Cancer

IS - 21

ER -

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Sammanfattning

Ämnesklassifikation (UKÄ)

FN:s Globala mål

Tillgång till dokument

Fingeravtryck

Citera det här